MedCalcHub stores your favorites, history, and saved calculations locally in your browser using localStorage. This data never leaves your device.
Optional advertising, when enabled, may use third-party cookies or similar technologies. You can accept or reject advertising below.
Calculates the calcium-phosphate product used in renal risk assessment for vascular calcification.
Clinical decision-support tool for qualified healthcare professionals. Results are not a diagnosis and should not replace professional clinical judgment.
The calcium-phosphate (Ca × P) product estimates the combined mineral load that may promote metastatic and vascular calcification. It is most often used in patients with chronic kidney disease (CKD) and CKD–mineral and bone disorder (CKD-MBD), where disordered calcium and phosphate homeostasis accelerates extraskeletal calcification. Values below 55 mg²/dL² are generally considered acceptable. Products of 55–70 mg²/dL² indicate an elevated calcification burden and warrant closer monitoring of phosphate binders, dietary phosphate, and vitamin D analogue dosing. Products of ≥70 mg²/dL² are critically elevated and are associated with a markedly increased risk of soft-tissue and vascular calcification, warranting urgent review of the CKD-MBD management plan. The product should be interpreted alongside intact PTH, alkaline phosphatase, serum bicarbonate, vitamin D metabolites, and the clinical picture. An elevated Ca × P product reflects the combined effect of hypercalcemia, hyperphosphatemia, or both; the underlying cause determines management. Limitations include that it does not directly quantify tissue calcification, does not replace imaging when calcification is suspected, and should not be used in isolation to guide therapy. KDIGO guidelines recommend maintaining calcium and phosphate levels toward the normal range rather than targeting a specific product threshold.
Specialty
Internal MedicineCategory
NephrologyDifficulty
Basic
Estimated Time
30 seconds
Version
1.0
Last Updated
2026-08-06
Formula
Keywords
Normal Range
< 55 mg²/dL²
| Classification | Range |
|---|---|
Acceptable | <55.1 |
Elevated — increased calcification risk | 55–70 |
Critically elevated — high calcification risk | ≥70 |
Calculates the calcium–phosphate product to assess the risk of metastatic and vascular calcification, particularly in chronic kidney disease and dialysis patients.
The calcium-phosphate product = serum calcium (mg/dL) x serum phosphate (mg/dL), used to assess the risk of vascular and soft-tissue calcification in chronic kidney disease.
Serum calcium in mg/dL, used as a factor in the product.
Serum phosphate in mg/dL, used as a factor in the product.
A product <55 mg²/dL² is acceptable. Values of 55–70 mg²/dL² are elevated with increased calcification risk, and values ≥70 mg²/dL² are critically elevated with high calcification risk.
An elevated calcium–phosphate product is associated with increased vascular calcification and cardiovascular morbidity, making it an important monitoring target in CKD-MBD management.
A 65-year-old woman on hemodialysis has serum calcium 9.5 mg/dL and phosphate 6.0 mg/dL.
Inputs:
Expected Result: Calcium–phosphate product = 9.5 × 6.0 = 57 mg²/dL² — elevated, indicating increased calcification risk; review phosphorus intake and phosphate binder use.
Reduce dietary phosphorus, use phosphate binders, and optimize dialysis adequacy. Avoid excessive calcium-based binders to prevent hypercalcemia.
In CKD and dialysis patients, elevated calcium and phosphate drive vascular and soft-tissue calcification, which is linked to increased cardiovascular risk.
Disclaimer: This calculator is intended for educational and clinical decision support purposes only. Manage the underlying mineral abnormalities rather than treating the number alone.